vadimezan has been researched along with fosbretabulin in 17 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (fosbretabulin) | Trials (fosbretabulin) | Recent Studies (post-2010) (fosbretabulin) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 588 | 21 | 310 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (82.35) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laux, WT; Palmer, BN; Rutland, MD; Siim, BG; Wilson, WR | 1 |
| Horsman, MR; Murata, R; Overgaard, J | 1 |
| Beauregard, DA; Brindle, KM; Hill, SA; Pedley, RB | 1 |
| Lepler, S; Mercer, E; Rojiani, AM; Siemann, DW | 1 |
| Horsman, MR; Murata, R | 1 |
| Thorpe, PE | 1 |
| Chaplin, DJ; Horsman, MR; Siemann, DW | 2 |
| Bukowski, RM; Cooney, MM; Ortiz, J; Remick, SC | 1 |
| Breidahl, T; Horsman, MR; Maxwell, RJ; Nielsen, FU; Stødkilde-Jørgensen, H | 1 |
| Eskens, FA; Hinnen, P | 1 |
| Griffiths, JR; McPhail, LD; Robinson, SP | 1 |
| Chen, G; Horsman, MR; Pang, Q; Pedersen, M; Stødkilde-Jørgensen, H | 1 |
| Castaldo, V; Colantuoni, G; Gridelli, C; Maione, P; Rossi, A; Rossi, E; Sacco, PC | 1 |
| Kim, S; Mitchison, TJ; Peshkin, L | 1 |
| Busk, M; Horsman, MR; Iversen, AB | 1 |
| Bertelsen, LB; Bohn, AB; Falborg, L; Horsman, MR; Shen, YY; Stødkilde-Jørgensen, H | 1 |
6 review(s) available for vadimezan and fosbretabulin
| Article | Year |
|---|---|
Vascular targeting agents as cancer therapeutics.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Cell Division; Clinical Trials as Topic; Diphosphates; Genetic Therapy; Humans; Hypoxia; Immunotoxins; Ligands; Models, Biological; Necrosis; Neoplasms; Organophosphorus Compounds; Peptides; Radioimmunotherapy; Stilbenes; Time Factors; Up-Regulation; Xanthones | 2004 |
Vascular-targeting therapies for treatment of malignant disease.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Combined Modality Therapy; Endothelium, Vascular; Neoplasms, Experimental; Organophosphorus Compounds; Stilbenes; Xanthones | 2004 |
Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Endothelium, Vascular; Humans; Neoplasms; Organophosphorus Compounds; Stilbenes; Xanthones | 2005 |
Current development status of small-molecule vascular disrupting agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Disease Models, Animal; Drug Therapy, Combination; Humans; Neoplasms; Neovascularization, Pathologic; Regional Blood Flow; Stilbenes; Tubulin Modulators; Xanthones | 2006 |
Vascular disrupting agents in clinical development.
Topics: Animals; Antineoplastic Agents; Blood Vessels; Humans; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Regional Blood Flow; Stilbenes; Tubulin Modulators; Xanthones | 2007 |
Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diketopiperazines; Endothelial Cells; Humans; Imidazoles; Lung Neoplasms; Pericytes; Piperazines; Stilbenes; Sulfonamides; Xanthones | 2009 |
11 other study(ies) available for vadimezan and fosbretabulin
| Article | Year |
|---|---|
Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Fibrosarcoma; Humans; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Organotechnetium Compounds; Oximes; Radionuclide Imaging; Radiopharmaceuticals; Stilbenes; Xanthenes; Xanthones | 2000 |
Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood; Digestive System; Dose-Response Relationship, Drug; Female; Kidney; Liver; Lung; Mice; Mice, Inbred C3H; Muscles; Neoplasm Transplantation; Neoplasms; Perfusion; Skin; Spleen; Stilbenes; Time Factors; Tissue Distribution; Tumor Cells, Cultured; Urinary Bladder; Xanthenes; Xanthones | 2001 |
Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Contrast Media; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Mice, SCID; Stilbenes; Transplantation, Heterologous; Xanthenes; Xanthones | 2002 |
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Necrosis; Neovascularization, Pathologic; Sarcoma, Experimental; Stilbenes; Tumor Cells, Cultured; Xanthenes; Xanthones | 2002 |
Combination of vascular targeting agents with thermal or radiation therapy.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Radiation; Flavonoids; Hyperthermia, Induced; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Stilbenes; Temperature; Time Factors; Tumor Cells, Cultured; X-Rays; Xanthenes; Xanthones | 2002 |
The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Female; Hydrogen-Ion Concentration; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Nucleosides; Organophosphorus Compounds; Phosphates; Stilbenes; Time Factors; Treatment Outcome; Xanthones | 2006 |
Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Female; Hemoglobins; Magnetic Resonance Imaging; Neoplasms; Neovascularization, Pathologic; Rats; Rats, Inbred WF; Stilbenes; Xanthones | 2007 |
The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
Topics: Animals; Antineoplastic Agents; Body Water; Diffusion; Female; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Regional Blood Flow; Stilbenes; Time Factors; Xanthones | 2008 |
Vascular disrupting agent drug classes differ in effects on the cytoskeleton.
Topics: Animals; Antineoplastic Agents, Phytogenic; Capillary Permeability; Cell Line; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Mice; Microtubules; Neoplasms, Experimental; Neovascularization, Pathologic; Stilbenes; Xanthones | 2012 |
Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.
Topics: Animals; Antineoplastic Agents; Blood Vessels; Chemoradiotherapy; Diphosphates; Female; Flavonoids; Hypoxia; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Oxygen; Stilbenes; X-Ray Therapy; Xanthones | 2013 |
Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Carcinoma; Cell Movement; Cell Survival; Cell Tracking; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Female; Fetal Blood; Humans; Indium Radioisotopes; Mice; Mice, Nude; Stilbenes; Xanthones | 2014 |